Trial Profile
A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tralokinumab (Primary)
- Indications Alopecia areata
- Focus Pharmacodynamics
- 20 Aug 2018 Status changed from recruiting to completed.
- 11 Apr 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
- 11 Apr 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.